Flat trading for AstraZeneca stock as GBX13,003 support underpins price

Traders Union
All News
Financial News
AstraZeneca slides 0.33% to GBX13196

Highlights

AstraZeneca secured FDA approval for Truqap as the first targeted therapy for PTEN-deficient metastatic prostate cancer, supported by positive Phase III data.
FDA also granted priority review to Ultomiris for IgAN and CALYPSO Phase 3 data showed eneboparatide achieved key endpoints in hypoparathyroidism.
AZN/GBX remains under broad selling pressure with strong bearish momentum, oversold signals, and an expected range of GBX12,929.10 to GBX13,462.90 over the next 2–3 days.

FDA approvals fail to offset persistent selling in AZN shares

AstraZeneca received approval from the US Food and Drug Administration for Truqap (capivasertib) in combination with abiraterone and prednisone as a first targeted treatment option for adult patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, a milestone enabled by positive Phase III trial data and use of an FDA-authorized diagnostic test. The company also reported that positive Phase 3 CALYPSO results for eneboparatide showed normalization of serum calcium and reduced conventional supplement requirements in chronic hypoparathyroidism. In addition, the US FDA granted priority review for a supplemental biologics license application for Ultomiris (ravulizumab) in immunoglobulin A nephropathy (IgAN), though price action has remained under broader selling pressure.

Bearish momentum intensifies as oversold signals dominate technicals

AZN is trading below the MA-20 at GBX13,467.72 and MA-50 at GBX13,543.65 on the H1 chart, while also remaining under the MA-200 at GBX13,586.42 on the daily timeframe. The Ichimoku Kijun (GBX13,003.00) provides immediate support. Technical momentum indicators confirm a strong bearish bias: MACD and ADX both indicate pronounced selling pressure, RSI stands at 33.9 (Sell), and both CCI and BBP signal an oversold market. The Awesome Oscillator delivers a sell signal, while Stoch RSI is Neutral on the session.

Elevated downside risk as price stalls within volatile range

The expected price range for the next 2–3 trading days is GBX12,929.10 to GBX13,462.90, reflecting the typical volatility band relative to current levels. Downside risk remains elevated, with high probability for further weakness and a reversal currently considered unlikely. The baseline scenario sees AZN moving sideways within this corridor; however, a close above resistance could trigger a bullish breakout, while loss of immediate support would open the door to another leg lower.

Anton Kharitonov, expert at Traders Union, underscores AstraZeneca’s strong regulatory news but sees persistent technical weakness in the stock. He notes that despite FDA approvals and positive clinical data, bearish momentum dominates while price remains under key moving averages and technical selling signals persist. Downside risk prevails, with further weakness likely unless resistance is reclaimed. "Until AZN reclaims GBX13,467.72, I remain cautious and expect price to drift within its current range or lower."

Earlier, analysts highlighted ongoing technical weakness in AstraZeneca shares despite positive clinical and regulatory developments. The current technical setup reinforces this bearish outlook, with traders advised to closely monitor the GBX13,003.00 support level as a decisive barrier for potential further downside.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.